Two Drugs Approved for NPM1-Mutated Leukemia

By News Health
1 hour Ago

(MedPage Today) — The FDA has approved two targeted menin inhibitors for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML).
Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1-mutated…

Source link : https://www.medpagetoday.com/hematologyoncology/leukemia/118506

Author :

Publish date : 2025-11-13 19:16:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

RFK Jr. 'Diss Track'; Med Student Qualifies for Olympic Trials; Infant Formula PSA

Second Menin Inhibitor Approved for Mutated R/R AML

Here's What RFK Jr., FDA Got Wrong About Menopausal Hormone Therapy

Inside the UK’s Battle Against Counterfeit Drugs

Pediatrician Killed in Crash; Neurosurgeon's Gun Arrest; Army Ob/Gyn Lawsuit

Noninvasive Imaging Test Provides Answers in Angina With No Obstructive Arteries